Product · Engineering · Research

Daniel
Gouvignon.

Product leader and technology consultant based in Perth, Western Australia. Co-founder and Head of Product at Hatchet. I write about product strategy, technology, and independent investment research.

Connect on LinkedIn

Available

Experience10+ yrs

LocationPerth, WA

FocusProduct & AI

ResearchingASX micro-caps

Now

buildingTwoStreams — workforce management for gig-economy and event labour
Locatour — real-world adventure game that turns public parks into a map you level up by actually going outside

researchingASX micro-caps, particularly healthcare technology and diagnostics. Also software development, product design and AI

locationWestern Australia

statusAvailable for consulting engagements

Writing

Oct 2026

Peptide (Incretin) Drugs and the Liver: Where Resonance Health FitsHow incretin drugs change the demand for liver and body-composition imaging, where Resonance Health fits, and what the unproven fibrosis device still has to show.

Sept 2026

Resonance Health (ASX:RHT) — Updates & AnnouncementsASX announcements, upcoming catalysts, and news coverage tracked weekly. Price context for each announcement. Updated every Monday.

Aug 2026

Resonance Health (ASX:RHT) — Shareholder Investment Review, August 2026A plain-English deep-dive into Resonance Health following its first profitable full year. Revenue up 42%, self-funded, cash-generative, and holding a near-term fibrosis-diagnostic catalyst. What the business is worth on standard sums, what the competition looks like, and what to watch next.

Career

2015–